- Home
- HMST vs IKT Comparison
HMST vs IKT Comparison
Compare HMST & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- IKT
- Stock Information
- Founded
- HMST 1921
- IKT 2008
- Country
- HMST United States
- IKT United States
- Employees
- HMST N/A
- IKT N/A
- Industry
- HMST Major Banks
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- IKT Health Care
- Exchange
- HMST Nasdaq
- IKT Nasdaq
- Market Cap
- HMST 191.6M
- IKT 159.2M
- IPO Year
- HMST 2012
- IKT 2020
- Fundamental
- Price
- HMST $10.74
- IKT $2.77
- Analyst Decision
- HMST Buy
- IKT Strong Buy
- Analyst Count
- HMST 2
- IKT 2
- Target Price
- HMST $14.75
- IKT $6.50
- AVG Volume (30 Days)
- HMST 195.0K
- IKT 288.1K
- Earning Date
- HMST 01-27-2025
- IKT 11-14-2024
- Dividend Yield
- HMST N/A
- IKT N/A
- EPS Growth
- HMST N/A
- IKT N/A
- EPS
- HMST N/A
- IKT N/A
- Revenue
- HMST $169,710,000.00
- IKT $1.00
- Revenue This Year
- HMST N/A
- IKT N/A
- Revenue Next Year
- HMST $17.03
- IKT N/A
- P/E Ratio
- HMST N/A
- IKT N/A
- Revenue Growth
- HMST N/A
- IKT N/A
- 52 Week Low
- HMST $8.09
- IKT $1.12
- 52 Week High
- HMST $16.10
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- HMST 48.97
- IKT 44.07
- Support Level
- HMST $9.36
- IKT $2.62
- Resistance Level
- HMST $11.34
- IKT $2.89
- Average True Range (ATR)
- HMST 0.51
- IKT 0.28
- MACD
- HMST 0.09
- IKT -0.06
- Stochastic Oscillator
- HMST 54.18
- IKT 23.94
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.